Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations

Conclusion: Continuation of crizotinib therapy after RECIST-PD in Chinese NSCLC patients with positive ALK/ROS1 mutations is feasible in clinical practice.

Source: Journal of Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Jun Liu, Shaohua Cui, Feng Pan, Yiqian Ni, Hua Zhong, Liwen Xiong, Bo Jin, Tianqing Chu, Aiqin Gu, Liyan Jiang Tags: Research Paper Source Type: research